Menu

دكتور جمال الدين عصمت

دكتوراة أمراض الكبد و الجهاز الهضمى و الامراض المتوطنة, كلية الطب جامعة القاهرة.

الدكتور جمال رائد في مجال أمراض الجهاز الهضمي والكبد، قام بوضع الطرق القياسية الدولية للكشف عن و تصنيف مرض البلهارسيا الكبدية بواسطة الموجات فوق الصوتية لمنظمة الصحة العالمية. أجرى الدكتور جمال أيضًا عدد لا مثيل له من الانشطة البحثية الدولية و شارك فى تحرير العديد من المجلات الطبية و نشر الكثير من الكتب الطبية الدولية.

– أمراض الكبد و الجهاز الهضمى و الامراض المتوطنة.

– كلية طب القصر العينى, جامعة القاهرة.

– 39 عاما من الخبرة العملية.

– رئيس الجمعية الدولية لدراسة الكبد.

– مدير مراكز أمراض الكبد بوزارة الصحة.

– استشاري زراعة الكبد بمستشفيات  قصر العيني.

–  استشاري بمنظمة الصحة العالمية لعلاج فيروس التهاب الكبد الوبائي B.

– مدير وحدة أمراض البلهارسيا بكلية الطب جامعة القاهرة.

– مدير وحدة الابحاث الدولية بوزارة الصحة.

– رئيس وحدة أمراض الجهاز الهضمي والكبد ، مستشفى القاهرة الفاطمية.

– مدير البرنامج التدريبي للموجات فوق الصوتية على البطن بنقابة الأطباء المصرية.

– منسق البرامج التدريبية للدراسات العليا فى أمراض الكبد والجهاز الهضمي بوزارة الصحة.

 – مدير وحدة الكبد بمستشفى المنيل التخصصي.

– مؤسس و رئيس مركز القصر العينى لالتهاب الكبد الفيروسى.

– نائب رئيس جامعة القاهرة للدراسات العليا والبحث العلمي.

– عضو الجمعية الامريكية للامراض المتوطنة.

– زميل جامعة ماريلاند في بالتيمور.

– زميل مستشفى إدوارد هيريوت في ليون بفرنسا.

– عضو مجلس إدارة الجمعية المصرية لأمراض الكبد.

– عضو الجمعية الطبية المصرية للامراض المتوطنة و الطفيليات و الامراض المعدية.

– عضو الجمعية الطبية المصرية للموجات فوق الصوتية.

– عضو الجمعية الطبية المصرية لامراض الجهاز الهضمى.

– عضو جمعية اصدقاء مرضى الكبد فى العالم العربى.

الجوائز التى حصل عليها:

– من 1973 إلى 1979  جائزة الإنجاز و التقدير  الأكاديمي: لمدة 6 سنوات. 

– 1979 التخرج مع مرتبة الشرف كلية الطب جامعة القاهرة. 

– 1998 جائزة طبيب القاهرة المثالى من نقابة الأطباء المصرية. 

– 2008 رئيس مؤتمر الكبد الدولي ، سان فرانسيسكو. 

– 2010 الجائزة الفخرية الوطنية في الطب.  

Abdel-Wahab M, Esmat G, Milad M, Abdel Razek S, Strickland G (1989): Characteristicsonographic pattern of schistosomal hepatic fibrosis. Am, J.Trop. Med Hyg, 40 (1), 72-6.

  1. Abdel-Wahab M, Esmat G, Narooz S, Yosery A, Struewing J, Strickland G(1990):Sonographic studies of school children in a village endemic for Schistsomamansoni. Transactions of theRoyal Society Tropical Medicine 88, 69-73.
  2. Abdel-Wahab M, Esmat G(1992): The value of Ultrasonography in assessment of portal hypertensionin hepatosplenicSchistosomiasis. Mem. Inst. Oswaldo Cruz, Rio de Janerio, vol.87 suppl. IV, pp.143-7.
  3. Abdel-Wahab G, Esmat G, Strickland G (1992): Grading of Hepatic Schistosomiasis by the use ofultrasonography. Am J Trop Med Hyg, 46(4): 403-8.
  4. Abdel-Wahab M, Esmat G, Ramzy I, Fouad R, Abdel-Rahman M, Yosery A, NaroozS, Strickland G(1992): Schistosoma haematobium infection Egyptian school children: Demonstration of both hepatic and urinary tract morbidity by ultrasonography. Transactions of the Royal Society ofTropical Medicine and Hygiene, 86(4): 406-9.
  5. Bassily S, Strickland G, Abdel-Wahab M, Esmat G, Narooz S, El-Masr N.,Constantine N, Pstruewing J (1992): Efficacy of Hepatitis “B” vaccination in primary school childrenfrom village endemic for Schistosomamansoni. Rio de Jenerio, vol. 87 suppl. I.V, pp. 143-7.
  6. Abdel-Wahab M, Ramzy I, Esmat G, El-Kaffas H, Strickland G (1992): Ultrasound ofdetecting Schisotosmahaematobium urinary tract complications comparison with Radiographic procedures. TheJournal of Urology, 148: 346-50.
  7. Abdel-Wahab M, Esmat G, Farag A, El-Borey Y, Strickland G (1993): Ultrasonographicpredictions of esophageal varices in Schistosomamansoni Am J of Gastroenterology ,88(4), 560-3.
  8. Abdel-Wahab M, Yosery A, Narooz S, Esmat G, El Hak S, Nasif S, Strickland G(1993):Is Schistosomamansoni replacing Schistosomahaematobium in Fayoum? Am J Trop Med Hyg, 49(6):560-3.
  9. Abdel- Wahab M, Zakaria S, Kamel M, Abdel Khalq M, Mabrouk M, Salama H,Esmat G, Thomas D, Strickland G (1994): High seroprevelance of hepatitis C infection among risk groups in Egypt. Am J Trop Med Hyg, 51(5):563-7
  10. Kamel M, Miller F, El-Masry A, Zakaria S, Khatab M, Esmat G, Ghaffar Y(1994):Epidemiology of Schistosomamansoni, hepatitis “B” and Hepatitis “C”infections in Egypt. Annals ofTropical Medicine and Parasitology, 88, 501-9.
  11. Bakr A, Khalil M, Esmat G (1997): Acute cholecystitis is an indication for laparoscopiccholecystectomy: a prospective study. JSLS ; 1:119-124.
  12. Abdel Wahab M, Esmat G, El Boraey Y, Ramzy I, Medhat E, Stuckland S (2000): The epidemiology of schistosomiasis in Egypt: methods, training and quality control of clinical and ultrasound examinations. American J of Tropical Medicine and Hygiene, 62(2): 17-20.
  13. Abdel Wahab M, Esmat G, Medhat E, Narooz S, Ramzy I, El Boraey Y, Stuckland S(2000): The epidemiology of schistosomiasis in Egypt: Menofia governarate. American J of Tropical Medicine and Hygiene, 62(2): 28-34.
  14. Abdel Wahab M, Esmat G, Ramzy I, Narooz S, Medhat E, Ibrahim M, El Boraey Y,Strickland S (2000): The epidemiology of schistosomiasis in Egypt: Fayoum governarate. American J of Tropical Medicine and Hygiene, 62(2): 55-64.
  15. Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail N, Esmat G, Fix A (2002): Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg,67(4): 436-42.
  16. Esmat G, Abouzied A, Mohamed MK, Abdel-Hamid M, Elrazki MS, Ismail SA, AbdelAziz F, Mikhail N, Fix A, Strickland GT, Sjogren M (2002): Treatment with Peg Interferonalpha 2-b (PEG INF) plus ribavirin compared to Interferon alpha-2b (INF alfa-2b) plus Ribavirin onsubjects with chronic hepatitis C infected with HCV genotype 4 . Hepatology, 36(4):364A
  17. Esmat G, , Zakaria S, Khatab H, Abdel-Hamid M, Anwar M, Elrazki MS, El-Daly M,Elkafrawi S, Hasan A, Shaheen A, Ismail SA, Sjogren M Abouzied A (2002): Impact of hepatitis C virus (HCV) genotype and viral load on the biochemical and histopathological liver profiles inEgyptian patients infected with HCV. Hepatology, 36(4):535A
  18. Esmat G, Abouzied AM, Ismail A, Saleh SM, Said M, Anwar M, Abdel Aziz F,Shaheen A, Ahmed RA, Abdel Hamid M, Zalata KR, Fix AD, Strickland GT, SjogrenM. : Treatment with peg-interferon alfa-2b (peg-inf) plus ribavirin compared to interferon alfa-2b (ifnalfa 2b)plus ribavirin on subjects with chronic hepatitis c infected with HCV genotype 4. Tropical Medicine andHygiene. August 2002, Vol. 67 No. 2: 131-132
  19. Gamal Esmat, A.M Abouzied, Fatma Abdel-Aziz, M K Mohamed, Mohamed Abdel- Hamid, M S El Raziky, S A Ismail, K R Zalata, N N Mikhail : Treatment with peg-interferonalfa-2b (PEG-Ifn) plus ribavirin compared to interferon alfa-2b (INF alfa-2b) plus ribavirin on subjects withchronic hepatitis c infected with HCV genotype 4. Hepatology. October 2002, Vol. 36, No. 4, pt 2 of 2 : 364A
  20. G. Emsat, M. K. Mohamed, M. Abdel Hamid, K. Zalata, H. Khatab, M. El Batanony,A. M. Abouzied, M. El Raziky, A. M. Shaheen, A. Ismail. G.T. Strickland. A. Fix, M.SjogrenSjogren. The impact of steatosis on baseline characteristics and end of treatment response for chronichepatitis (C) genotype 4 patients treated with interferon. Journal of Hepatology. April 2003, Vol. 38,Supplement No.2, 139
  21. G. Esmat, M. Al Raziky, A. Abouzied, M. Kamal, M. Abdel Hamid, F. Abdel Aziz, A. AA Shaheen, N. Mikhail, T. Strickland, M. Sjogren. Impact of schistosomal infection on interferon response in genotype 4 chronic hepatitis C patients. Viral Hepatitis and Liver disease, April 2003,Sydney, Page 153
  22. G.E. Esmat et al, Sustained virological response (SVR) to pegylated interferon therapy in patients withgenotype 4 chronic HCV. Gut Supplement No.6, Vol. 52(2003)
  23. Gamal Esmat, Amr Abouzied, M Abdel-Hamid, M K Mohamed, K Zalata, M E ElRaziky, S A Ismail, M Said, A Hasan, M Anwar, A Shaheen, F Abdel ziz, N NMikhail, A Ismail, Alan Fix, Thomas G Strickland, Maria H Sjogren. Results of arandomized clinical trial of genotype 4 infected subjects when treated with standard or pegylated interferon alfa- 2b in combination with ribavirin. Hepatology, October 2003, Vol. 38, No. 4, Suppl. 1: 314A.
  24. M. S. El Raziky, M. El-Hawary, N. El- Koofy, S. Okasha, M. Kotb, K. Salama, G.EsmatEsmat, M. El- Raziky, A. M. Abouzied and H. El Karaksy (2004): Hepatitis C virusinfection in Egyptian children: Single center experience. Journal of Viral Hepatitis, 2004,11, 471-6.
  25. Ola Nada, Mohamed Abdel-Hamid, Alaa Ismail, Laila El-Shabrawy, Karima F.S.Sidhom, Nafissa M.A. El-Badawy, Faten A.A. Ghazal. Mai El-Daly, Sherif El- Kafrawy, Gamal Esmat, Christopher A. Loffredo: The role of the tumor necrosis factor(TNF)-Fas L and HCV in the development of hepatocellular carcinoma, Journal of ClinicalVirology. 2005 in press.

27.Esmat G, Yosry A, El-Serafi M, Omar A, Doss W, Hosny A, Ghali A, Sabry H,Attia H, Kamel S, Said M, Gabali H, Lee SK, Tanaka K. Donor outcomes in rightlobe adult living donor liver transplantation: single-center experience inEgypt.Transplant Proc. 2005 Sep;37(7):3147-50.

28.Bakr I, Rekacewicz C, El Hosseiny M, Ismail S, El Daly M, El-Kafrawy S,Esmat G, Hamid MA, Mohamed MK, Fontanet A. Higher clearance of hepatitis Cvirus infection in females compared with males. Gut. 2006 Aug;55(8):1183-7

29.Mohamed MK, Bakr I, El-Hoseiny M, Arafa N, Hassan A, Ismail S, Anwar M,Attala M, Rekacewicz C, Zalata K, Abdel-Hamid M, Esmat G, Fontanet A. HCV-related morbidity in a rural community of Egypt. Med Virol. 2006 Sep;78(9):1185-9.

30.Zakaria S, Fouad R, Shaker O, Zaki S, Hashem A, El-Kamary SS, Esmat G, Zakaria S. Changing patterns of acute viral hepatitis at a major urban referralcenter in Egypt Clin Infect Dis. 2007 Feb 15;44(4):e30-6

31.Esmat, G Metwally M, Zalata KR, Gadalla S, Abdel-Hamid M, Abouzied A, Shaheen AA, El-Raziky M, Khatab H, El-KafrawySMikhail N, Magder LS, Afdhal NH, Strickland GT. Evaluation of serum biomarkers of fibrosis and injury inEgyptian patients with chronic hepatitis C. J hepatol. 2007, Apr;46(4):620-7, Epub 2007 Jan

  1. 32.Abdel-Hamid M, El-Daly M, Molnegren V, El-Kafrawy S, Abdel-Latif S, Esmat G, Strickland GT, Loffredo C, Albert J, Widell A. Genetic diversity in hepatitis C virusin Egyptand possible association with hepatocellular carcinoma. J gen virol. 2007 May;88(Pt 5):1526-31.

33.El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-KoofyN,Mohsen N, Mansour S, Shaheen A, Abdel Hamid M, El-Karaksy H. Prevalence and riskfactors of asymptomatic hepatitis C virus infection in Egyptian children, World JGastroenterol. 2007 Mar 28;13(12):1828-32.

34.El-Karaksy H, Nomachi S, Esmat G, El-Serafy M, Kamel RR, El-Ansary A, Refaat S, Tanaka K. Equal outcome of living-related liver transplantation forWilson’s disease from heterozygote and nonheterozygote donors: A report of abrother and sister, Indian J Med Sci. 2007 May;61(5):286-8.

35.El-Hawary MA, El-Raziky MS, Esmat G, Soliman H, Abouzied A, El-Raziky M, El- Akel W, El-Sayed R, Shebl F, Shaheen AA, El-Karaksy H. Assessment of hepaticfibrosis in pediatric cases with hepatitis C virus in Egypt. World J Gastroenterol.2007 May 28;13(20):2846-51. PMID: 17569121 [PubMed – in process]

36.Zekri AR, Haleem HA, Esmat GE, Bahnassy AA, El-Din HM, Hafez MM, SharabyAF, Sharaf H, Zakaria MS. Immunomodulators, sFas and Fas-L as potentialnoninvasive predictors of IFN treatment in patients with HCV genotype-4. J ViralHepat. 2007 Jul;14(7):468-77.

  1. Sylvia Males, Rita Raafat Gad, Gamal Esmat, Hasan Abobakr, Mohamed Anwar,Claire Rekacewicz, Mostafa El Hoseiny, Khaled Zalata, Mohamed Abdel-Hamid,Pierre Bedossa, Stanislas Pol, Mostafa K Mohamed and Arnaud Fontanet. Serumalpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.Antiviral Therapy 2007; 12: 797-803.
  2. Ashraf A. Tabll, Samy B. Khalil, Reem M. El-Shenawy,GamalEsmat, AmrHelmy, Abdel Fattah Attallah,and Mostafa K. El-Awady.Establishment of Hybrid CellLines Producing Monoclonal Antibodies to a Synthetic Peptide from the E1 Region ofthe Hepatitis C Virus, Journal of Immunoassay & Immunochemistry, 29: 91–104,2008.
  3. Yosry A, Abdel-Rahman M, Esmat G, El-Serafy M, Omar A, Doss W, Zayed N, SaidM, Ismail T, Hosny A, Marawan E, El-Malt O, Kamel RR, Hatata Y, El-Taweel A,Ghali A, Sabri H, Kamel S, El-Gabaly H. Recurrence of hepatitis C virus (genotype 4)infection after living-donor liver transplant in Egyptian patients. ExpClin Transplant. 2009 Sep;7(3):157-63.
  4. Esmat G, El Akel W, Metwally M, Soliman A, Doss W, Hamid MA, Kamal M,Zalata K, Khattab H, El-Kassas M, Esmat M, Hasan A, El-Raziky M. Improvement ofsteatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian JGastroenterol. 2009 Mar-Apr;28(2):45-8.
  5. Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N,Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, EsmatG, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, SalamaM, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H,Elwakil R; Jury of the APASL Consensus Development Meeting 29 January 2008 onLiver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensusrecommendations of the Asian Pacific Association for the Study of the Liver (APASL).Hepatol Int. 2009 Jun;3(2):323-33.
  6. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R,Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S,Fontanet A, Mohamed MK. Response to pegylated interferon alfa-2a and ribavirin inchronic hepatitis C genotype 4. J Med Virol. 2009 Sep;81(9):1576-83.
  7. El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek M, MetwallyM, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G,Strickland GT. A randomized controlled trial to assess the safety and efficacy ofsilymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine. 2009 May;16(5):391-400.
  8. Abdel-Rahman N Zekri, Hanaa M Alam El-Din, Abeer A Bahnassy, Naglaa AZayed, Waleed S Mohamed, Suzan H El-Masry, Sayed K Gouda and Gamal Esmat. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptianpatients with hepatitis C virus genotype-4. Comp Hepatol. 2010 Jan 5;9.
  9. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sabry M, Helmy H, El- Hennawy A, Fouad H. Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatr Diabetes. 2009 Dec 23. 46. Zekri AR, Moharram RA, Mohamed WS, Bahnassy AA, Alam El-Din HM, Abo- Shadi MM, Zayed NA, El-Magzangy H, Abdel-Aziz AO, EsmatG.Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma isassociated with repression of interferon regulatory factor-1. Eur J GastroenterolHepatol. 2009 Oct 26. 47. Zekri AR, Alam El-Din HM, Bahnassy AA, Zayed NA, Mohamed WS, El-MasrySH, Gouda SK, Esmat G. Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors ofhepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. CompHepatol. 2010 Jan 5;9(1):1.
  10. Mohammed RH, Elmakhzangy HI, Gamal A, Mekky F, El Kassas M,Mohammed N, Hamid MA, Esmat G. Prevalence of rheumatologic manifestations ofchronic hepatitis C virus infection among Egyptians. ClinRheumatol. 2010 Apr 22.
  11. Mostafa A, Mohamed MK, Saeed M, Hasan A, Fontanet A, Godsland I, Coady E,Esmat G, El-Hoseiny M, Abdul-Hamid M, Hughes A, Chaturvedi N. Hepatitis Cinfection and clearance: impact on atherosclerosis and cardiometabolic risk factors.GutGut. 2010 Aug;59(8):1135-40.
  12. Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, OcamaP, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G.Treatment of chronic hepatitis B virus infection in resource-constrained settings:expert panel consensus. Liver Int. 2010 Nov 28.
  13. Fathy A, Eldin MM, Metwally L, Eida M, Abdel-Rehim M, Esmat G. Interferontherapy shifts natural killer subsets among Egyptian patients with chronic hepatitis C.BrazBraz J Infect Dis. 2010 Aug;14(4):398-405.

52.El-Karaksy H, Anwar GH, El-Raziky MS, El-Hawary M, Hashem M, El-Sayed R, El- Shabrawi M, Mohsen N, Fouad H, Esmat G. Anti-HCV prevalence among diabetic andnon-diabetic Egyptian children. Curr Diabetes Rev. 2010 Nov;6(6):388-92.

  1. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sabry M, Helmy H, El- Hennawy A, Fouad H. Prevalence of hepatic abnormalities in a cohort of Egyptianchildren with type 1 diabetes mellitus. Pediatr Diabetes. 2010 Nov;11(7):462-70
  2. Zekri AR, Moharram RA, Mohamed WS, Bahnassy AA, Alam El-Din HM, Abo- Shadi MM, Zayed NA, El-Magzangy H, Abdel-Aziz AO, Esmat G. Diseaseprogression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma isassociated with repression of interferon regulatory factor-1. Eur J GastroenterolHepatol. 2010 Apr;22(4):450-6.
  3. Bader el-Din NG, Abd el-Meguid M, Tabll AA, Anany MA, Esmat G, Zayed N,Helmy A, el-Zayady AR, Barakat A, el-Awady MK. Human cytomegalovirus infectioninhibits response of chronic hepatitis-C-virus-infected patients to interferon-basedtherapy. J GastroenterolHepatol. 2011 Jan;26(1):55-62.
  4. El Awady MK, Anany MA, Esmat G, Zayed N, Tabll AA, Helmy A, El ZayadyAR, Abdalla MS, Sharada HM, El Raziky M, El Akel W, Abdalla S, Bader El Din NG.Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 genedetermines response of hepatitis C virus patients to interferon therapy. JGastroenterolHepatol. 2011 May;26(5):843-50.
  5. Hashem M, El-Karaksy H, Shata MT, Sobhy M, Helmy H, El-Naghi S, Galal G,Ali ZZ, Esmat G, Abdelwahab SF, Strickland GT, El-Kamary SS. Strong hepatitis Cvirus (HCV)-specific cell-mediated immune responses in the absence of viremia orantibodies among uninfected siblings of HCV chronically infected children. J Infect Dis.2011 Mar 15;203(6):854-61.
  6. El Tayebi HM, Salah W, El Sayed IH, Salam EM, Zekri AR, Zayed N, Salem ES,Esmat G, Abdelaziz AI. Expression of insulin-like growth factor-II, matrixmetalloproteinases, and their tissue inhibitors as predictive markers in the peripheralblood of HCC patients. Biomarkers. 2011 Jun;16(4):346-54.
  7. Hamdi N, El-Akel W, El-Serafy M, Esmat G, Sarrazin C, AbdelazizAI.Transcriptional Response of MxA, PKR and SOCS3 to Interferon-Based Therapy inHCV Genotype 4-Infected Patients and Contribution of p53 to Host Antiviral Response.IntervirologyIntervirology. 2011 May 20.
  8. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D,Chen CH, Dou X, El Khayat H, Elshazly M, Esmat G, Guan R, Han KH, Koike K,Largen A, McCaughan G, Mogawer S, Monis A, Nawaz A, Piratvisuth T, Sanai FM,Sharara AI, Sibbel S, Sood A, Suh DJ, Wallace C, Young K, Negro F. A systematicreview of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011 Jul;31 Suppl 2:61-80.
  9. Wiersma ST, McMahon B, Pawlotsky JM, Thio CL, Thursz M, Lim SG, OcamaP, Esmat G, Maimuna M, Bell D, Vitoria M, Eramova I, Lavanchy D, Dusheiko G;Treatment of chronic hepatitis B virus infection in resource-constrained settings:expert panel consensus. Liver Int. 2011 Jul;31(6):755-61.
  10. Vignier N, Esmat G, Sharkawy AE, Hassany M, Bonnard P, Delarocque- Astagneau E, Said M, Raafat R, El-Hoseiny M, Fontanet A, Mohamed MK, Vray M. Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infectedpatients in Egypt. J Viral Hepat. 2011 Jul;18(7).
  11. Elhawary EI, Mahmoud GF, El-Daly MA, Mekky FA, Esmat GG, Abdel-HamidM. Association of HCV with diabetes mellitus: an Egyptian case-control study. Virol J.2011 Jul 26;8:367.
  12. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M,Delarocque-Astagneau E, Dusheiko G, Esmat G, Esteban R, Goldberg D, Gore C,Lok AS, Manns M, Marcellin P, Papatheodoridis G, Peterle A, Prati D, Piorkowsky N,Rizzetto M, Roudot-Thoraval F, Soriano V, Thomas HC, Thursz M, Valla D, vanDamme P, Veldhuijzen IK, Wedemeyer H, Wiessing L, Zanetti AR, Janssen HL. Thestate of hepatitis B and C in Europe: report from the hepatitis B and C summitconference. J Viral Hepat. 2011 Sep;18 Suppl 1:1-16.
  13. Esmat G, Hashem M, El-Raziky M, El-Akel W, El-Naghy S, El-Koofy N, El- Sayed R, Ahmed R, Atta-Allah M, Hamid MA, El-Kamary SS, El-Karaksy H. Riskfactors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver Int. 2011 Sep 15.
  14. G. Esmat, M. El-Bendary, S. Zakarya, M. A. Ela and K. Zalata. Role ofHelicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with orwithout hepatocellular carcinoma: possible association with disease progression. JViral Hepat. 2011 .

الاعتمادات الأكاديمية

فيديوهات وصور

احدث تقنيات جراحات التجميل

دكتور عمر نوح يتحدث عن عن احدث تقنيات جراحات التجميل في مصر وتطورها ،وهل هناك فريق بين جراحات التجميل وعمليات التجميل

مقالات دكتور جمال الدين عصمت جميل

Shopping Basket

حجز موعد مع

دكتور جمال الدين عصمت

Menu